Literature DB >> 26123706

How to Improve the Safe and Effective Use of Doxorubicin in Children with Cancer.

John N van den Anker1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26123706     DOI： 10.1007/s40262-015-0300-4

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  10 in total

1.  Canadian cancer statistics at a glance: cancer in children.

Authors:  Larry F Ellison; Prithwish De; Leslie S Mery; Paul E Grundy
Journal:  CMAJ       Date:  2009-02-17       Impact factor: 8.262

2.  Cardiotoxicity after childhood cancer: beginning with the end in mind.

Authors:  Steven E Lipshultz; M Jacob Adams
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

3.  Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer.

Authors:  Swantje Völler; Joachim Boos; Miriam Krischke; Gudrun Würthwein; Nina E Kontny; Alan V Boddy; Georg Hempel
Journal:  Clin Pharmacokinet       Date:  2015-11       Impact factor: 6.447

4.  Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer.

Authors:  Markhaba Tukenova; Catherine Guibout; Odile Oberlin; Françoise Doyon; Abdeddahir Mousannif; Nadia Haddy; Sylvie Guérin; Hélène Pacquement; Albertine Aouba; Mike Hawkins; Dave Winter; Jean Bourhis; Dimitri Lefkopoulos; Ibrahima Diallo; Florent de Vathaire
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

5.  Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.

Authors:  Henk Visscher; Colin J D Ross; S Rod Rassekh; Amina Barhdadi; Marie-Pierre Dubé; Hesham Al-Saloos; George S Sandor; Huib N Caron; Elvira C van Dalen; Leontien C Kremer; Helena J van der Pal; Andrew M K Brown; Paul C Rogers; Michael S Phillips; Michael J Rieder; Bruce C Carleton; Michael R Hayden
Journal:  J Clin Oncol       Date:  2011-09-06       Impact factor: 44.544

6.  Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study.

Authors:  Helena J van der Pal; Elvira C van Dalen; Michael Hauptmann; Wouter E Kok; Huib N Caron; Cor van den Bos; Foppe Oldenburger; Caro C Koning; Flora E van Leeuwen; Leontien C Kremer
Journal:  Arch Intern Med       Date:  2010-07-26

7.  Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.

Authors:  H Visscher; C J D Ross; S R Rassekh; G S S Sandor; H N Caron; E C van Dalen; L C Kremer; H J van der Pal; P C Rogers; M J Rieder; B C Carleton; M R Hayden
Journal:  Pediatr Blood Cancer       Date:  2013-02-25       Impact factor: 3.167

8.  Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia.

Authors:  Josefine Palle; Britt-Marie Frost; Curt Peterson; Göran Gustafsson; Marit Hellebostad; Jukka Kanerva; Kjeld Schmiegelow; Gudmar Lönnerholm
Journal:  Anticancer Drugs       Date:  2006-04       Impact factor: 2.248

Review 9.  The emerging era of pharmacogenomics: current successes, future potential, and challenges.

Authors:  J W Lee; F Aminkeng; A P Bhavsar; K Shaw; B C Carleton; M R Hayden; C J D Ross
Journal:  Clin Genet       Date:  2014-05-09       Impact factor: 4.438

10.  Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia.

Authors:  J Gregers; H Gréen; I J Christensen; K Dalhoff; H Schroeder; N Carlsen; S Rosthoej; B Lausen; K Schmiegelow; C Peterson
Journal:  Pharmacogenomics J       Date:  2015-01-13       Impact factor: 3.550
  10 in total
  4 in total

1.  A database of pediatric drug effects to evaluate ontogenic mechanisms from child growth and development.

Authors:  Nicholas P Giangreco; Nicholas P Tatonetti
Journal:  Med (N Y)       Date:  2022-06-24

2.  Effects of genetic polymorphisms on the sulfation of doxorubicin by human SULT1C4 allozymes.

Authors:  Saud A Gohal; Mohammed I Rasool; Ahsan F Bairam; Eid S Alatwi; Fatemah A Alherz; Maryam S Abunnaja; Amal A El Daibani; Katsuhisa Kurogi; Ming-Cheh Liu
Journal:  J Biochem       Date:  2021-10-12       Impact factor: 3.387

3.  Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial.

Authors:  Miriam Krischke; Georg Hempel; Swantje Völler; Nicolas André; Maurizio D'Incalci; Gianni Bisogno; Wolfgang Köpcke; Matthias Borowski; Ralf Herold; Alan V Boddy; Joachim Boos
Journal:  Cancer Chemother Pharmacol       Date:  2016-10-21       Impact factor: 3.333

4.  Chemotherapy induced damage to spermatogonial stem cells in prepubertal mouse in vitro impairs long-term spermatogenesis.

Authors:  Federica Lopes; Prathima Tholeti; Satish K Adiga; Richard A Anderson; Rod T Mitchell; Norah Spears
Journal:  Toxicol Rep       Date:  2020-12-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.